Monopar Therapeutics Announces FDA Authorization for Expanded Access Program of Investigational Agents MNPR-101-Zr and MNPR-101-Lu in Collaboration with Excel Diagnostics
11/6 13:14
Monopar Therapeutics and EDNOC announce FDA authorization for Expanded Access Program for investigational agents targeting advanced cancers....